title: Cytotoxic hepatosplenic gammadelta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma chains of the T-cell receptor. Biologic and clinical features.
abstract: OBJECTIVE
  Hepatosplenic gd T-cell lymphoma is a rare entity of peripheral T-cell lymphomas. We characterized in detail the first case of hepatosplenic gd -T-cell lymphoma following acute myeloid leukemia.
  
  
  METHODS
  Hepatosplenic gd -T-cell lymphoma was diagnosed in a woman who had been in complete remission (CR) of acute myeloid leukemia (AML) for two years. Improvement but no objective response of the disease was observed after various types of chemotherapy. CR was achieved after related donor stem cell transplantation. Thirteen months later relapse of hepatosplenic gd T-cell lymphoma was diagnosed. While being prepared for a second transplantation the patient developed meningeal lymphoma and died. The patient's lymphoma cells were studied by immunologic, functional and molecular techniques.
  
  
  RESULTS
  Lymphoma cells expressed the gd T-cell receptor (TCR), CD2, CD3, CD5, CD7, CD38, CD45, CD161 (NKR-P1), TIA and Ki67. Further analysis revealed expression of Vd1 and two distinct TCRg chains, Vg3 and Vg9, by the malignant cell clone. The clonality of the T-cells was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) followed by sequencing of TCR Vg3, Vg9 and Vd1 junctional regions. Clone-specific PCR was negative at diagnosis of AML and was positive at all times during follow-up of the hepatosplenic gd T-cell lymphoma. The lymphoma cells mediated strong natural killer cell-like cytotoxic activity, possibly explained by expression of CD161 and a lack of killer inhibitory receptor.
  
  
  CONCLUSIONS
  Several so far undescribed features were observed in this case of hepatosplenic gd T-cell lymphoma, such as T-cell lymphoma following AML, expression of two distinct T-cell receptor g-chains, and an unexpected cytotoxic phenotype.
authors.affiliation: Department of Medicine III, Hematology/Oncology, University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany. e.weidmann@em.uni-frankfurt.de
authors.forename: E
authors.initials: E
authors.lastname: Weidmann
authors.forename: T
authors.initials: T
authors.lastname: Hinz
authors.forename: S
authors.initials: S
authors.lastname: Klein
authors.forename: D K
authors.initials: DK
authors.lastname: Schui
authors.forename: S
authors.initials: S
authors.lastname: Harder
authors.forename: S
authors.initials: S
authors.lastname: Kriener
authors.forename: D
authors.initials: D
authors.lastname: Kabelitz
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: P S
authors.initials: PS
authors.lastname: Mitrou
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology; D008113:Liver Neoplasms; D016399:Lymphoma, T-Cell / Q000276:immunology; D016609:Neoplasms, Second Primary; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011252:Pregnancy Complications, Neoplastic; D016692:Receptors, Antigen, T-Cell, gamma-delta; D013160:Splenic Neoplasms
chemical_list: D016692:Receptors, Antigen, T-Cell, gamma-delta